Volume | 105,832 |
|
|||||
News | (2) | ||||||
Day High | 12.635 | Low High |
|||||
Day Low | 12.37 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Mineralys Therapeutics Inc | MLYS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
12.39 | 12.37 | 12.635 | 12.58 | 12.69 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,028 | 105,832 | $ 12.50 | $ 1,322,788 | - | 5.85 - 17.44 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:10:33 | formt | 100 | $ 12.58 | USD |
Mineralys Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
517.51M | 41.11M | - | 0 | -71.9M | -1.75 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Mineralys Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MLYS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 13.20 | 13.67 | 12.37 | 12.94 | 203,588 | -0.62 | -4.70% |
1 Month | 13.12 | 13.67 | 11.6901 | 12.88 | 126,256 | -0.54 | -4.12% |
3 Months | 13.08 | 15.00 | 10.37 | 12.89 | 130,956 | -0.50 | -3.82% |
6 Months | 8.16 | 16.905 | 7.29 | 12.48 | 156,877 | 4.42 | 54.17% |
1 Year | 15.90 | 17.44 | 5.85 | 11.90 | 177,611 | -3.32 | -20.88% |
3 Years | 21.10 | 21.98 | 5.85 | 13.08 | 181,702 | -8.52 | -40.38% |
5 Years | 21.10 | 21.98 | 5.85 | 13.08 | 181,702 | -8.52 | -40.38% |
Mineralys Therapeutics Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. |